<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078281</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-BEN-2020-01</org_study_id>
    <nct_id>NCT05078281</nct_id>
  </id_info>
  <brief_title>Patients With Severe Eosinophilic Asthma Treated With Benralizumab</brief_title>
  <acronym>Asthma</acronym>
  <official_title>Predictive Response Factors in Respondent Patients and Results After Monoplane Switch in Patients With Severe Eosinophilic Asthma Treated With Benralizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective, multicenter, routine clinical practice study with consecutive inclusion of&#xD;
      adult patients with severe eosinophilic asthma receiving benralizumab treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective study studying severe eosinophilic asthma. Patients with this disease who are&#xD;
      on benralizumab treatment for at least 4 months before the start of the study will be&#xD;
      included.&#xD;
&#xD;
      The purpose of this study is to analyze the predictive factors of response in patients with&#xD;
      this type of disease treated with benralizumab, who obtain a complete response during their&#xD;
      follow-up.&#xD;
&#xD;
      The results of the study will be obtained through the review of medical records, where&#xD;
      demographic characteristics such as age, gender and smoking will be assessed; presence of&#xD;
      comorbidities; clinical-functional variables; response variables (exercises, cycles of oral&#xD;
      corticosteroids, admissions, visits to the emergency room or unscheduled, cumulative dose of&#xD;
      oral corticosteroids, absenteeism from work) and side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response predictors in patients treated with benralicumab.</measure>
    <time_frame>Up to 60 weeks.</time_frame>
    <description>To analyze response predictors in patients with severe eosinophilic asthma under treatment with benralizumab who obtain a complete response during their follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study the response variables to benralizumab.</measure>
    <time_frame>Up to 60 weeks.</time_frame>
    <description>Number of visits to the emergency room or hospital admissions observed since the beginning of the study.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Asthma; Eosinophilic</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with severe eosinophilic asthma receiving benralizumab.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with severe eosinophilic asthma receiving benralizumab belonging to the health&#xD;
        area of each center, in the Pulmonology and Allergology units, will be included. Patients&#xD;
        must have at least 4 months of benralizumab treatment at the start of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (over 18 years of age) diagnosed with severe eosinophilic asthma on&#xD;
             benralizumab treatment for at least 4 months from the start of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom no previous history is available or who do not meet the inclusion&#xD;
             criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Gómez-Ballesteros Fernández</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Gómez-Ballesteros Fernández</last_name>
    <phone>955008000</phone>
    <email>ana.gomezbastero@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Perez</last_name>
    <phone>600162458</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Gómez-Ballesteros Fernández</last_name>
      <phone>955 00 80 00</phone>
    </contact>
    <contact_backup>
      <last_name>Carlos García Pérez</last_name>
      <phone>600 162 458 (65 24 58)</phone>
      <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

